Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.64 |
| ▸ | LMNA | P02545 | 8/20 | 0.64 |
| ▸ | TSHR | P16473 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.64 |
| ▸ | PGR | P06401 | 4/20 | 0.64 |
| ▸ | AR | P10275 | 4/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.63 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | SHBG | P04278 | 4/20 | 0.55 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.55 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6898510 | 1.00 | CYP3A4 (0.64) | CYP3A4LMNATSHRMAPTCYP17A1 | |
| SCHEMBL6901756 | 0.89 | CYP3A4 (0.68) | CYP3A4LMNATSHRMAPTCYP17A1 | |
| SCHEMBL6901750 | 0.89 | CYP3A4 (0.68) | CYP3A4LMNATSHRMAPTCYP17A1 | |
| SCHEMBL4264019 | 0.89 | CYP3A4 (0.71) | CYP3A4LMNATSHRMAPTCYP17A1 | |
| SCHEMBL4264017 | 0.89 | CYP3A4 (0.71) | CYP3A4LMNATSHRMAPTCYP17A1 | |
| SCHEMBL6902011 | 0.85 | CYP3A4 (0.65) | CYP3A4LMNATSHRMAPTCYP17A1 | |
| SCHEMBL6902019 | 0.85 | CYP3A4 (0.65) | CYP3A4LMNATSHRMAPTCYP17A1 | |
| SCHEMBL6902015 | 0.85 | CYP3A4 (0.65) | CYP3A4LMNATSHRMAPTCYP17A1 | |
| SCHEMBL6902002 | 0.85 | CYP3A4 (0.65) | CYP3A4LMNATSHRMAPTCYP17A1 | |
| SCHEMBL6897111 | 0.84 | CYP3A4 (0.69) | CYP3A4LMNATSHRMAPTCYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180169069-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS LLC (US) | 2018-06-21 | — | — | US | claimed |
| US-8110565-B2 | Of the ACE inhibitor ramipril; controlling the melting point by mixing with the free acid with the ramipril ethyl or methyl ester prodrug and a pressure sensitive adhesive carrier; improved pharmacokinetics; sustained release | NOVEN PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | claimed |
| EP-2374458-A1 | Combination of an ACE inhibitor and an NSAID for use in ameliorating cachexia/SIRS | Vicus Therapeutics SPE 1, LLC (US) | 2011-10-12 | — | — | EP | claimed |
| EP-2374508-A1 | Combination of angiotension receptor blockers (ARB) and NSAIDs for use in ameliorating cachexia | Vicus Therapeutics SPE 1, LLC (US) | 2011-10-12 | — | — | EP | claimed |
| US-7846916-B2 | Enhanced drug delivery in transdermal systems | Noven Pharamaceticals, Inc. (US) | 2010-12-07 | — | — | US | claimed |
| US-20090215852-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | CHROMA GROUP, INC. | 2009-08-27 | — | — | US | claimed |
| US-20090117197-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS LLC (US) | 2009-05-07 | — | — | US | claimed |
| EP-1990049-A2 | Combination therapy of beta-blockers and non-steroidal anti-inflammatory drugs (NSAID) | Vicus Therapeutics SPE 1, LLC (US) | 2008-11-12 | — | — | EP | claimed |
| US-20080167280-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2008-07-10 | — | — | US | claimed |
| EP-1865779-A4 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS SPE 1 LLC (US) | 2008-06-04 | — | — | EP | claimed |
| CN-100391462-C | Enhanced drug delivery in transdermal systems | NOVEN PHARMA (US) | 2008-06-04 | — | — | CN | claimed |
| EP-1865779-A2 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | Vicus Therapeutics SPE 1, LLC (US) | 2007-12-19 | — | — | EP | claimed |
| US-7214381-B2 | Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels | ANTARES PHARMA IPL AG (CH) | 2007-05-08 | — | — | US | claimed |
| WO-2006102476-A2 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS SPE 1, LLC (US) | 2006-09-28 | — | — | WO | claimed |
| EP-0801561-B1 | COMPOSITION AND METHODS FOR TRANSDERMAL DELIVERY OF ACID-LABILE DRUGS | NOVEN PHARMA (US) | 2005-04-06 | — | — | EP | claimed |
| US-20040235808-A1 | Androstanes as androgen receptor modulators | WANG JIABING (US) | 2004-11-25 | — | — | US | claimed |
| EP-1429779-A2 | ANDROSTANES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-06-23 | — | — | EP | claimed |
| WO-2003026568-A2 | ANDROSTANES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-04-03 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | VAN BOGAERT GINA (BE) | 2026-01-15 | — | — | US | disclosed |
| US-20250281509-A1 | SEQUENTIAL HORMONE THERAPY TO IMPROVE SURVIVAL AND ENHANCE RESPONSE TO IMMUNE THERAPY IN MEN WITH PROSTATE CANCER | THE JOHNS HOPKINS UNIVERSTY | 2025-09-11 | — | — | US | disclosed |
| WO-2025054607-A1 | COMPOSITIONS AND METHODS FOR TREATING SARCOPENIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20250032509-A1 | Testosterone Ester Triglyceride Formulations | ANTARES PHARMA, INC. (US) | 2025-01-30 | — | — | US | disclosed |
| US-12144817-B2 | Testosterone ester triglyceride formulations | ANTARES PHARMA, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| EP-3335740-B1 | MEDICAL HYDROGEL | UPM KYMMENE CORP (FI) | 2024-07-24 | — | — | EP | disclosed |
| US-20230416822-A1 | DETECTION AND TREATMENT OF CONDITIONS CHARACTERIZED BY PERFUSION SHORTAGE | FALCON BIOSCIENCE, LLC | 2023-12-28 | — | — | US | disclosed |
| US-11850306-B2 | Method for drying hydrogel comprising nanofibrillar cellulose and a dried hydrogel comprising nanofibrillar cellulose | UPM-KYMMENE CORPORATION (FI) | 2023-12-26 | — | — | US | disclosed |
| WO-2023223235-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | PURNA PHARMACEUTICALS NV (BE) | 2023-11-23 | — | — | WO | disclosed |
| EP-4153995-A2 | DETECTION AND TREATMENT OF CONDITIONS CHARACTERIZED BY PERFUSION SHORTAGE | Falcon Bioscience, LLC (US) | 2023-03-29 | — | — | EP | disclosed |
| US-11534526-B2 | Medical hydrogel | UPM-KYMMENE CORPORATION (FI) | 2022-12-27 | — | — | US | disclosed |
| CN-110087633-B | Method for drying hydrogel comprising nanofibrillar cellulose and dried hydrogel comprising nanofibrillar cellulose | 芬欧汇川集团 | 2022-08-09 | — | — | CN | disclosed |
| CN-110072567-B | Medical hydrogel | 芬欧汇川集团 | 2022-04-12 | — | — | CN | disclosed |
| US-20220079955-A1 | Testosterone Ester Triglyceride Formulations | ANTARES PHARMA, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| WO-2021236836-A2 | DETECTION AND TREATMENT OF CONDITIONS CHARACTERIZED BY PERFUSION SHORTAGE | FALCON BIOSCIENCE, LLC (US) | 2021-11-25 | — | — | WO | disclosed |
| US-11123352-B2 | Testosterone ester triglyceride formulations | ANTARES PHARMA, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200289528-A1 | Testosterone Ester Triglyceride Formulations | ANTARES PHARMA, INC. (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3675868-A1 | TESTOSTERONE ESTER TRIGLYCERIDE FORMULATIONS | Antares Pharma, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| US-20200197310-A1 | Technology for Preparation of Macromolecular Microspheres | NEXBIO, INC. | 2020-06-25 | — | — | US | disclosed |
| US-10646495-B2 | Testosterone ester triglyceride formulations | ANTARES PHARMA, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20200078305-A1 | A METHOD FOR DRYING HYDROGEL COMPRISING NANOFIBRILLAR CELLULOSE AND A DRIED HYDROGEL COMPRISING NANOFIBRILLAR CELLULOSE | UPM-KYMMENE CORPORATION (FI) | 2020-03-12 | — | — | US | disclosed |
| US-10583086-B2 | Technology for preparation of macromolecular microspheres | ANSUN BIOPHARMA, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| EP-3335695-B1 | A METHOD FOR FREEZE-DRYING HYDROGEL COMPRISING NANOFIBRILLAR CELLULOSE, A FREEZE-DRIED MEDICAL HYDROGEL COMPRISING NANOFIBRILLAR CELLULOSE, AND A HYDROGEL COMPRISING NANOFIBRILLAR CELLULOSE | UPM KYMMENE CORP (FI) | 2020-02-05 | — | — | EP | disclosed |
| EP-3335696-B1 | A METHOD FOR DRYING CELL-FREE TISSUE EXTRACT IN A HYDROGEL COMPRISING NANOFIBRILLAR CELLULOSE AND A DRIED HYDROGEL COMPRISING NANOFIBRILLAR CELLULOSE AND CELL-FREE TISSUE EXTRACT | UPM KYMMENE CORP (FI) | 2019-12-18 | — | — | EP | disclosed |
| US-20190343889-A1 | A METHOD FOR DRYING CELL-FREE TISSUE EXTRACT IN A HYDROGEL COMPRISING NANOFIBRILLAR CELLULOSE AND A DRIED HYDROGEL COMPRISING NANOFIBRILLAR CELLULOSE AND CELL-FREE TISSUE EXTRACT | UPM KYMMENE CORP (FI) | 2019-11-14 | — | — | US | disclosed |
| US-20190336643-A1 | MEDICAL HYDROGEL | UPM-KYMMENE CORPORATION (FI) | 2019-11-07 | — | — | US | disclosed |
| CN-110234314-A | The method of dry acellular tissue extract and the dried hydrogel comprising nanometer fibril cellulose and acellular tissue extract in the hydrogel comprising nanometer fibril cellulose | 芬欧汇川集团 | 2019-09-13 | — | — | CN | disclosed |
| CN-110087633-A | The method of the dry hydrogel comprising nanometer fibril cellulose and the hydrogel of the drying comprising nanometer fibril cellulose | 芬欧汇川集团 | 2019-08-02 | — | — | CN | disclosed |
| CN-110072567-A | Medical aquogel | 芬欧汇川集团 | 2019-07-30 | — | — | CN | disclosed |
| WO-2019046582-A1 | TESTOSTERONE ESTER TRIGLYCERIDE FORMULATIONS | ANTARES PHARMA, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-20190000802-A1 | DRUG COMBINATION PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USING THEM | VICUS THERAPEUTICS LLC (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180169069-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS LLC (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2018109281-A1 | A METHOD FOR DRYING HYDROGEL COMPRISING NANOFIBRILLAR CELLULOSE AND A DRIED HYDROGEL COMPRISING NANOFIBRILLAR CELLULOSE | UPM-KYMMENE CORPORATION (FI) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018109282-A1 | A METHOD FOR DRYING CELL-FREE TISSUE EXTRACT IN A HYDROGEL COMPRISING NANOFIBRILLAR CELLULOSE AND A DRIED HYDROGEL COMPRISING NANOFIBRILLAR CELLULOSE AND CELL-FREE TISSUE EXTRACT | UPM-KYMMENE CORPORATION (FI) | 2018-06-21 | — | — | WO | disclosed |
| EP-3335696-A1 | A METHOD FOR DRYING CELL-FREE TISSUE EXTRACT IN A HYDROGEL COMPRISING NANOFIBRILLAR CELLULOSE AND A DRIED HYDROGEL COMPRISING NANOFIBRILLAR CELLULOSE AND CELL-FREE TISSUE EXTRACT | UPM-Kymmene Corporation (FI) | 2018-06-20 | — | — | EP | disclosed |
| EP-3335695-A1 | A METHOD FOR DRYING HYDROGEL COMPRISING NANOFIBRILLAR CELLULOSE AND A DRIED HYDROGEL COMPRISING NANOFIBRILLAR CELLULOSE | UPM-Kymmene Corporation (FI) | 2018-06-20 | — | — | EP | disclosed |
| US-20180071219-A1 | Technology for Preparation of Macromolecular Microspheres | NEXBIO, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180028449-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2018-02-01 | — | — | US | disclosed |
| US-20170333396-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS LLC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9682043-B2 | Method of preparation of mixed phase co-crystals with active agents | MEDCRYSTALFORMS, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170079920-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2017-03-23 | — | — | US | disclosed |
| US-20160331762-A1 | TRANSDERMAL TESTOSTERONE DEVICE AND DELIVERY | NOVEN PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160235675-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160175436-A1 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES | VICUS THERAPEUTICS LLC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160158198-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS LLC (US) | 2016-06-09 | — | — | US | disclosed |
| EP-3028743-A2 | COMPOSITIONS FOR MUCOSITIS AND ONCOLOGY THERAPIES | Vicus Therapeutics, LLC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20160129018-A1 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES | VICUS THERAPEUTICS LLC (US) | 2016-05-12 | — | — | US | disclosed |
| US-9320742-B2 | Transdermal testosterone device and delivery | NOVEN PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160022820-A1 | TRANSDERMAL DELIVERY SYSTEM | ACRUX DDS PTY LTD. (AU) | 2016-01-28 | — | — | US | disclosed |
| US-20160008376-A1 | Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| WO-2016005599-A1 | COMPOSITIONS, METHODS AND USES FOR TREATING GENDER-BIASED IMMUNE DISORDERS | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | WO | disclosed |
| US-20150359746-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2015-12-17 | — | — | US | disclosed |
| US-20150290134-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | NEXBIO, INC. | 2015-10-15 | — | — | US | disclosed |
| US-9078810-B2 | Transdermal delivery system | ACRUX DDS PTY LTD (AU) | 2015-07-14 | — | — | US | disclosed |
| CN-104758253-A | Technology for preparation of macromolecular microspheres | NEXBIO INC | 2015-07-08 | — | — | CN | disclosed |
| US-20150050713-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8882729-B2 | Transdermal therapeutic system having stabilized membrane | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2014-11-11 | — | — | US | disclosed |
| US-8784893-B2 | Polymer formulations for delivery of bioactive agents | CARBYLAN THERAPEUTICS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140134150-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | ANSUN BIOPHARMA, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| CN-103784408-A | Technology for the preparation of microparticles | ANSUN BIOPHARMA INC | 2014-05-14 | — | — | CN | disclosed |
| US-20140099696-A1 | Technology for the Preparation of Microparticles | ANSUN BIOPHARMA, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-20140018435-A1 | Transdermal Delivery of Therapeutic Agents Using Poly (Amidoamine) Dendrimers | UNIV ILLINOIS CHICAGO (US) | 2014-01-16 | — | — | US | disclosed |
| US-8623419-B2 | Technology for preparation of macromolecular microspheres | ANSUN BIOPHARMA, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130317122-A1 | TRANSDERMAL DELIVERY SYSTEM | ACRUX DDS PTY LTD. (AU) | 2013-11-28 | — | — | US | disclosed |
| US-20130317462-A1 | TRANSDERMAL DELIVERY SYSTEM FOR HORMONES AND STEROIDS | ACRUX DDS PTY LTD. (AU) | 2013-11-28 | — | — | US | disclosed |
| CN-101883556-B | Transdermal delivery system for hormones and steroids | ACRUX DDS PTY LTD | 2013-05-29 | — | — | CN | disclosed |
| US-8414914-B2 | Compositions for mucosal delivery of agents | VIRUN, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| CN-101888830-B | Transdermal delivery system | ACRUX DDS PTY LTD | 2013-01-23 | — | — | CN | disclosed |
| US-20120308644-A1 | Compositions for mucosal delivery of agents | ARCHIMEDES LABORATORIES, INC. | 2012-12-06 | — | — | US | disclosed |
| EP-2506838-A1 | TRANSDERMAL TESTOSTERONE DEVICE AND DELIVERY | Noven Pharmaceuticals, INC. (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20120245537-A1 | TRANSDERMAL THERAPEUTIC SYSTEM HAVING STABILIZED MEMBRANE | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2012-09-27 | — | — | US | disclosed |
| US-8252323-B2 | Compositions for mucosal delivery of agents | VIRUN, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| EP-1768647-B1 | COMPOSITIONS COMPRISING A MUCOADHESIVE PROTEIN AND AN ACTIVE PRINCIPLE FOR MUCOSAL DELIVERY OF SAID AGENT | VIRUN INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20120141590-A1 | Technology for the Preparation of Microparticles | MALAKHOV MICHAEL (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120116062-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | ANSUN BIOPHARMA, INC. | 2012-05-10 | — | — | US | disclosed |
| US-8110565-B2 | Of the ACE inhibitor ramipril; controlling the melting point by mixing with the free acid with the ramipril ethyl or methyl ester prodrug and a pressure sensitive adhesive carrier; improved pharmacokinetics; sustained release | NOVEN PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| CN-101005828-B | Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents | VIRUN INC | 2012-01-11 | — | — | CN | disclosed |
| EP-2374458-A1 | Combination of an ACE inhibitor and an NSAID for use in ameliorating cachexia/SIRS | Vicus Therapeutics SPE 1, LLC (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2374508-A1 | Combination of angiotension receptor blockers (ARB) and NSAIDs for use in ameliorating cachexia | Vicus Therapeutics SPE 1, LLC (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-1406633-B1 | ENHANCED DRUG DELIVERY IN TRANSDERMAL SYSTEMS | NOVEN PHARMA (US) | 2011-10-05 | — | — | EP | disclosed |
| US-8025898-B2 | Of the ACE inhibitor ramipril by mixing with the ramipril (m)ethyl ester prodrug and a pressure sensitive adhesive carrier; improved pharmacokinetics; sustained release | NOVEN PHARMACEUTICALS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110158983-A1 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES | VICUS THERAPEUTICS, LLC | 2011-06-30 | — | — | US | disclosed |
| WO-2011068722-A1 | TRANSDERMAL TESTOSTERONE DEVICE AND DELIVERY | NOVEN PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20110129535-A1 | TRANSDERMAL TESTOSTERONE DEVICE AND DELIVERY | NOVEN PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | disclosed |
| US-20110117184-A1 | Compositions for mucosal delivery of agents | VIRUN, INC. | 2011-05-19 | — | — | US | disclosed |
| US-7906140-B2 | Compositions for mucosal delivery of agents | VIRUN, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20110033540-A1 | POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS | CARBYLAN THERAPEUTICS, INC. | 2011-02-10 | — | — | US | disclosed |
| CN-101969937-A | Transdermal therapeutic system having stabilized membrane | LOHMANN THERAPIE SYST LTS | 2011-02-09 | — | — | CN | disclosed |
| US-7879831-B2 | Steroid on carrier containing pressure sensitive adhesive | NOVEN PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7867986-B2 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| EP-2259844-A1 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES | Vicus Therapeutics SPE 1, LLC (US) | 2010-12-15 | — | — | EP | disclosed |
| US-7846916-B2 | Enhanced drug delivery in transdermal systems | Noven Pharamaceticals, Inc. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20100297032-A1 | TRANSDERMAL DELIVERY SYSTEM | ACRUX DDS PTY LTD. | 2010-11-25 | — | — | US | disclosed |
| CN-101888830-A | Transdermal delivery system | ACRUX DDS PTY LTD | 2010-11-17 | — | — | CN | disclosed |
| CN-101883556-A | Transdermal delivery system for hormones and steroids | ACRUX DDS PTY LTD | 2010-11-10 | — | — | CN | disclosed |
| US-20100279988-A1 | TRANSDERMAL DELIVERY SYSTEM FOR HORMONES AND STEROIDS | ACRUX DDS PTY LTD. | 2010-11-04 | — | — | US | disclosed |
| CN-101848704-A | Techniques for preparing microparticles | NEXBIO INC | 2010-09-29 | — | — | CN | disclosed |
| EP-2219603-A1 | TRANSDERMAL DELIVERY SYSTEM | Acrux DDS Pty Ltd (AU) | 2010-08-25 | — | — | EP | disclosed |
| EP-2214643-A1 | TRANSDERMAL DELIVERY SYSTEM FOR HORMONES AND STEROIDS | Acrux DDS Pty Ltd (AU) | 2010-08-11 | — | — | EP | disclosed |
| US-20100166874-A1 | Technology for Preparation of Macromolecular Microspheres | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-07-01 | — | — | US | disclosed |
| EP-2173327-A2 | TECHNOLOGY FOR THE PREPARATION OF MICROPARTICLES | Nexbio, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| CN-101677957-A | Polymer formulations for delivery of bioactive agents | CARBYLAN BIOSURGERY INC | 2010-03-24 | — | — | CN | disclosed |
| EP-2117513-A2 | POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS | Carbylan Biosurgery, Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009111648-A1 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES | VICUS THERAPEUTICS, LLC (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090215852-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | CHROMA GROUP, INC. | 2009-08-27 | — | — | US | disclosed |
| WO-2009055860-A1 | TRANSDERMAL DELIVERY SYSTEM | ACRUX DDS PTY LTD (AU) | 2009-05-07 | — | — | WO | disclosed |
| US-20090117197-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS LLC (US) | 2009-05-07 | — | — | US | disclosed |
| WO-2009055859-A1 | TRANSDERMAL DELIVERY SYSTEM FOR HORMONES AND STEROIDS | ACRUX DDS PTY LTD (AU) | 2009-05-07 | — | — | WO | disclosed |
| EP-2054052-A1 | DRUG COMBINATION PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USING THEM | Vicus Therapeutics SPE 1, LLC (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20090098207-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| CN-101404980-A | Preparation Technology of Macromolecular Microspheres | NEXBIO INC (US) | 2009-04-08 | — | — | CN | disclosed |
| WO-2009015286-A2 | TECHNOLOGY FOR THE PREPARATION OF MICROPARTICLES | NEXBIO, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| US-7456159-B2 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1990049-A2 | Combination therapy of beta-blockers and non-steroidal anti-inflammatory drugs (NSAID) | Vicus Therapeutics SPE 1, LLC (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1981483-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | Nexbio, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2008098019-A2 | POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS | CARBYLAN BIOSURGERY, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| US-7404965-B2 | Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels | ANTARES PHARMA IPL AG (CH) | 2008-07-29 | — | — | US | disclosed |
| US-20080167280-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080167365-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2008-07-10 | — | — | US | disclosed |
| EP-1865779-A4 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS SPE 1 LLC (US) | 2008-06-04 | — | — | EP | disclosed |
| CN-100391462-C | Enhanced drug delivery in transdermal systems | NOVEN PHARMA (US) | 2008-06-04 | — | — | CN | disclosed |
| US-7335379-B2 | Transdermal pharmaceutical formulation for minimizing skin residues | ANTARES PHARMA IPL AG (CH) | 2008-02-26 | — | — | US | disclosed |
| US-20080033027-A1 | Drug combination pharmaceutical compositions and methods for using them | VICUS THERAPEUTICS SPE 1, LLC (US) | 2008-02-07 | — | — | US | disclosed |
| WO-2008014471-A1 | DRUG COMBINATION PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USING THEM | VICUS THERAPEUTICS SPE 1, LLC (US) | 2008-01-31 | — | — | WO | disclosed |
| EP-1865779-A2 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | Vicus Therapeutics SPE 1, LLC (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007114881-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | NEXBIO, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070190163-A1 | Technology for preparation of macromolecular microspheres | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTE OF HEALTH | 2007-08-16 | — | — | US | disclosed |
| CN-101005828-A | Compositions comprising a mucoadhesive protein and an activeprinciple for mucosal delivery of said agents | VIRUN INC (US) | 2007-07-25 | — | — | CN | disclosed |
| US-7214381-B2 | Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels | ANTARES PHARMA IPL AG (CH) | 2007-05-08 | — | — | US | disclosed |
| US-20070098775-A1 | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels | ANTARES PHARMA IPL AG | 2007-05-03 | — | — | US | disclosed |
| EP-1768647-A1 | COMPOSITIONS COMPRISING A MUCOADHESIVE PROTEIN AND AN ACTIVE PRINCIPLE FOR MUCOSAL DELIVERY OF SAID AGENT | Virun, Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1307232-B1 | NOVEL COMPOSITION FOR TRANSDERMAL AND/OR TRANSMUCOSAL ADMINISTRATION OF ACTIVE COMPOUNDS THAT ENSURES ADEQUATE THERAPEUTIC LEVELS | ANTARES PHARMA IPL AG (CH) | 2007-03-07 | — | — | EP | disclosed |
| EP-1727520-A2 | METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVE AGENTS | MEDCRYSTALFORMS, LLC (US) | 2006-12-06 | — | — | EP | disclosed |
| US-7122198-B1 | Fast dissolving composition with prolonged sweet taste | PANACEA BIOTEC LIMITED (IN) | 2006-10-17 | — | — | US | disclosed |
| WO-2006102476-A2 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS SPE 1, LLC (US) | 2006-09-28 | — | — | WO | disclosed |
| EP-1406633-A4 | ENHANCED DRUG DELIVERY IN TRANSDERMAL SYSTEMS | NOVEN PHARMA (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20060153905-A1 | Transdermal pharmaceutical formulation for minimizing skin residues | ANTARES PHARMA, INC. | 2006-07-13 | — | — | US | disclosed |
| EP-1670433-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATION FOR MINIMIZING SKIN RESIDUES | Antares Pharma IPL AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| US-7026360-B1 | Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients | INPHARMA S.A. (CH) | 2006-04-11 | — | — | US | disclosed |
| CN-1239153-C | Transdermal therapeutic system based on polyacrylate-contact-bonding adhesives without functional groups | LOHMANN THERAPIE SYST LTS (DE) | 2006-02-01 | — | — | CN | disclosed |
| WO-2006009825-A1 | COMPOSITIONS COMPRISING A MUCOADHESIVE PROTEIN AND AN ACTIVE PRINCIPLE FOR MUCOSAL DELIVERY OF SAID AGENTS | VIRUN, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| EP-1021204-B1 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMA (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050281772-A1 | Compositions for mucosal delivery of agents | VIRUN, INC. | 2005-12-22 | — | — | US | disclosed |
| US-20050181041-A1 | Method of preparation of mixed phase co-crystals with active agents | MEDCRYSTALFORMS, LLC (US) | 2005-08-18 | — | — | US | disclosed |
| WO-2005055983-A2 | METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVE AGENTS | MEDCRYSTALFORMS, LLC (US) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005039531-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATION FOR MINIMIZING SKIN RESIDUES | ANTARES PHARMA IPL AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| EP-0801561-B1 | COMPOSITION AND METHODS FOR TRANSDERMAL DELIVERY OF ACID-LABILE DRUGS | NOVEN PHARMA (US) | 2005-04-06 | — | — | EP | disclosed |
| CN-1178699-C | Pharmaceutical Compsns. contg. compounds with activity for enhancement of absorption of active ingredients | — | 2004-12-08 | — | — | CN | disclosed |
| US-20040241219-A1 | Transdermal therapeutic system based on polyacrylate-contact-bonding adhesives without functional groups | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2004-12-02 | — | — | US | disclosed |
| US-20040235808-A1 | Androstanes as androgen receptor modulators | WANG JIABING (US) | 2004-11-25 | — | — | US | disclosed |
| CN-1545408-A | Transdermal therapeutic system based on polyacrylate adhesive patches without functional groups | LTS��������ϵͳ�ɷݹ�˾ | 2004-11-10 | — | — | CN | disclosed |
| CN-1543349-A | Enhanced drug delivery in transdermal systems | ŵ��ҩƷ��˾ | 2004-11-03 | — | — | CN | disclosed |
| EP-1429779-A2 | ANDROSTANES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-06-23 | — | — | EP | disclosed |
| EP-1406633-A1 | ENHANCED DRUG DELIVERY IN TRANSDERMAL SYSTEMS | NOVEN PHARMACEUTICALS, INC. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20040018241-A1 | Bioadhesive compositions and methods for topical administration of active agents | NOVEN PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| US-20030232073-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
| US-20030199426-A1 | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels | ANTARES PHARMA, INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030152615-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-20030152613-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-20030152614-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| EP-1325752-A2 | Composition for transdermal and/or transmucosal administration of active compounds which ensures adequate therapeutic levels | Antares Pharma IPL AG (CH) | 2003-07-09 | — | — | EP | disclosed |
| EP-1323430-A2 | Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels | Antares Pharma IPL AG (CH) | 2003-07-02 | — | — | EP | disclosed |
| EP-1323431-A2 | Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels | Antares Pharma IPL AG (CH) | 2003-07-02 | — | — | EP | disclosed |
| US-6562363-B1 | Bioadhesive compositions and methods for topical administration of active agents | NOVEN PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| EP-1307232-A1 | NOVEL COMPOSITION FOR TRANSDERMAL AND/OR TRANSMUCOSAL ADMINISTRATION OF ACTIVE COMPOUNDS THAT ENSURES ADEQUATE THERAPEUTIC LEVELS | Antares Pharma IPL AG (CH) | 2003-05-07 | — | — | EP | disclosed |
| WO-2003026568-A2 | ANDROSTANES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2002102390-A1 | ENHANCED DRUG DELIVERY IN TRANSDERMAL SYSTEMS | NOVEN PHARMACEUTICALS, INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002011768-A1 | NOVEL COMPOSITION FOR TRANSDERMAL AND/OR TRANSMUCOSAL ADMINISTRATION OF ACTIVE COMPOUNDS THAT ENSURES ADEQUATE THERAPEUTIC LEVELS | ANTARES PHARMA IPL AG (CH) | 2002-02-14 | — | — | WO | disclosed |
| US-6254558-B1 | Method for producing a therapeutic system in the form of plaster | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2001-07-03 | — | — | US | disclosed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | disclosed |
| US-6221383-B1 | BLEND OF AT LEAST TWO POLYMERS, OR AT LEAST ONE POLYMER AND A SOLUBLE POLYVINYLPYRROLIDONE, IN COMBINATION WITH A DRUG PROVIDES A PRESSURE-SENSITIVE ADHESIVE COMPOSITION FOR A TRANSDERMAL DRUG DELIVERY SYSTEM | NOVEN PHARMACEUTICALS, INC. | 2001-04-24 | — | — | US | disclosed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | disclosed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | disclosed |
| EP-1021204-A2 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| US-6024976-A | TRANSDERMAL DRUG DELIVERY WITH PRESSURE SENSITIVE ADHESIVE COMPOSITION OF POLYVINYLPYRROLIDONE WITH DRUG IN MULTILAYER PATCH | NOVEN PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-6024974-A | TRANSDERMAL DRUG DELIVERY | NOVEN PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| WO-1999015210-A2 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998053863-A2 | COMPOSITION AND METHODS FOR TRANSDERMAL DELIVERY OF ACID LABILE DRUGS | NOVEN PHARMACEUTICALS, INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| US-5798338-A | STEROID/BETA-CYCLODEXTRIN CLATHRATE; OXIDATION RESISTANCE | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-08-25 | — | — | US | disclosed |
| US-5719197-A | DRUG DELIVERY | NOVEN PHARMACEUTICALS, INC. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0801561-A2 | COMPOSITION AND METHODS FOR TRANSDERMAL DELIVERY OF ACID-LABILE DRUGS | NOVEN PHARMACEUTICALS, INC. (US) | 1997-10-22 | — | — | EP | disclosed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040086-A2 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996020699-A1 | COMPOSITION AND METHODS FOR TRANSDERMAL DELIVERY OF ACID-LABILE DRUGS | NOVEN PHARMACEUTICALS, INC. (US) | 1996-07-11 | — | — | WO | disclosed |
| US-5525727-A | ANALGESIC OR NARCOTIC ANTAGONIST | UNIVERSITY OF FLORIDA (US) | 1996-06-11 | — | — | US | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
| US-5187158-A | Sustained delivery of viricides | UNIVERSITY OF FLORIDA (US) | 1993-02-16 | — | — | US | disclosed |
| US-5008257-A | Penicillin or cephalosporin antibiotics | UNIVERSITY OF FLORIDA (US) | 1991-04-16 | — | — | US | disclosed |
| US-4900837-A | Brain-specific drug delivery of steroid sex hormones cleaved from pyridinium carboxylates and dihydro-pyridine carboxylate precursors | UNIVERSITY OF FLORIDA (US) | 1990-02-13 | — | — | US | disclosed |
| US-4880921-A | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1989-11-14 | — | — | US | disclosed |
| US-4824850-A | DIHYDROPYRIDINE-PYRIDINIUM SALT REDOX CARRIER | UNIVERSITY OF FLORIDA (US) | 1989-04-25 | — | — | US | disclosed |
| US-4622218-A | Testicular-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1986-11-11 | — | — | US | disclosed |
| US-4540564-A | DIHYDROPYRIDINE AND/OR PYRIDINIUM SALT REDOX CARRIER | UNIVERSITY OF FLORIDA (US) | 1985-09-10 | — | — | US | disclosed |
| US-4479932-A | DIHYDROPYRIDINE PYRIDINIUM SALT REDOX CARRIER | UNIVERSITY OF FLORIDA (US) | 1984-10-30 | — | — | US | disclosed |
| EP-0110955-A1 | BRAIN-SPECIFIC DRUG DELIVERY. | UNIV FLORIDA (US) | 1984-06-20 | — | — | EP | disclosed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | disclosed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279988-A1 | TRANSDERMAL DELIVERY SYSTEM FOR HORMONES AND STEROIDS | SHBG, PGR, NR5A1 | CYP3A4 405/4885LMNA 3386/4885TSHR 85/4885 |
| US-20220079955-A1 | Testosterone Ester Triglyceride Formulations | SHBG, NR5A1, HSD17B11 | CYP3A4 118/4885LMNA 498/4885TSHR 770/4885 |
| US-20250032509-A1 | Testosterone Ester Triglyceride Formulations | SHBG, NR5A1, HSD17B11 | CYP3A4 118/4885LMNA 498/4885TSHR 770/4885 |
| US-20100297032-A1 | TRANSDERMAL DELIVERY SYSTEM | S100A10, MMP20, TLR6 | CYP3A4 933/4885LMNA 3672/4885TSHR 1688/4885 |
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | NR5A1, SHBG, GNRHR | CYP3A4 1458/4885LMNA 796/4885TSHR 232/4885 |
| US-10646495-B2 | Testosterone ester triglyceride formulations | SHBG, NR5A1, HSD17B11 | CYP3A4 118/4885LMNA 498/4885TSHR 770/4885 |
| US-20160022820-A1 | TRANSDERMAL DELIVERY SYSTEM | S100A10, MMP20, TLR6 | CYP3A4 933/4885LMNA 3672/4885TSHR 1688/4885 |
| US-20130317122-A1 | TRANSDERMAL DELIVERY SYSTEM | S100A10, MMP20, TLR6 | CYP3A4 933/4885LMNA 3672/4885TSHR 1688/4885 |
| US-12144817-B2 | Testosterone ester triglyceride formulations | SHBG, NR5A1, HSD17B11 | CYP3A4 118/4885LMNA 498/4885TSHR 770/4885 |
| US-11123352-B2 | Testosterone ester triglyceride formulations | SHBG, NR5A1, HSD17B11 | CYP3A4 118/4885LMNA 498/4885TSHR 770/4885 |
| US-20200289528-A1 | Testosterone Ester Triglyceride Formulations | SHBG, NR5A1, HSD17B11 | CYP3A4 118/4885LMNA 498/4885TSHR 770/4885 |
| US-20110033540-A1 | POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS | BMP2, BMP6, BMP4 | CYP3A4 4757/4885LMNA 1101/4885TSHR 4548/4885 |
| US-20130317462-A1 | TRANSDERMAL DELIVERY SYSTEM FOR HORMONES AND STEROIDS | SHBG, PGR, NR5A1 | CYP3A4 405/4885LMNA 3386/4885TSHR 85/4885 |
| US-20040235808-A1 | Androstanes as androgen receptor modulators | SHBG, FSHR, AR | CYP3A4 695/4885LMNA 3934/4885TSHR 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.